Deloitte explores how energy companies can form renewable goals for right now

Carbon-neutral is the goal, but what can be done right now? Photo by Wuttisack Promchoo/Getty

The global energy mix is shifting from fossil fuels to renewables. There are abundant examples of both public and private organizations working hard to decarbonize the economy.

As this energy transformation or "Green Deal" gains momentum, new ecosystems are forming and new technologies are emerging. These developments are helping to grow renewables, develop new energy carriers, improve energy efficiency, reduce emissions, and create new markets for carbon and other by-products as part of an increasingly circular economy.

At the same time, many of these commonly pursued steps to decarbonization — such as increased electrification, wide-scale use of renewable energy, and intensifying energy efficiency measures — pose unique challenges.

Many participants in the energy and resources (E&R) industry have publicly declared their intention to become carbon neutral by 2050. While their long-term vision is clear, the more perplexing challenge for E&R companies lies in the immediate future.

Many companies are struggling to understand the material impacts that their stated goals are going to have on their valuations, operations, employees, and markets over the next few years.

Continue reading this article on Deloitte's website to learn how companies in certain sectors of the E&R industry — chemicals, oil and gas, mining and metals, and power, utilities, and renewables — can accelerate decarbonization over the next decade and achieve meaningful interim targets by 2030.

---

This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.

About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms. Copyright ©2020 Deloitte Development LLC. All rights reserved.

Trending News

Building Houston

 
 

Houston-based Melax Tech has developed multiple Natural language processing tools that are used by more than 650 health care and life science organizations. Photo via MelaxTech.com

Melax Tech Partners, a leader in natural language technology processing, announced a new partnership with the University of California at Irvine that will help researchers derive insights from the UCI Health Data Science Platform’s electronic health records system and improve patient care.

Melax will implement its signature text annotation tool LANN to pull information from clinical notes, and its CLAMP product to develop natural language processing customizations through the use of AI, according to a statement from the company.

“There has been a strong desire among UCI researchers to have the capability to analyze free-text clinical narrative data using cutting-edge NLP technologies," Kai Zheng, chief research information officer at UCI Health Affairs, says in a statement. "We are delighted to have this opportunity to work with Melax Tech to deploy their AI-driven annotation and analytics tools to help our researchers advance their research agenda by leveraging the vast amount of free-text data that our health system has accumulated in the past two decades.”

Natural language processing, or NLP, allows organizations and healthcare groups to sift through and analyze massive amounts of data at a rapid rate through the use of machine learning and AI. Houston-based Melax Tech, founded in 2017, has developed multiple NLP tools that are used by more than 650 health care and life science organizations, according to its website.

In addition to the recent partnership with UC Irvine, Melax has also recently partnered with Vanderbilt University Medical Center and the University of Western Pennsylvania on similar clinical projects.

Melax has also used its platforms to pull vital information from datasets relating to COVID-19, in both medical and social settings.

In March 2022, it was awarded a Phase 1 NIH Award, valued at $300,000, to develop informatics tools based on COVID-19 datasets with the San Diego Supercomputer Center at UC San Diego. The tool aims to help researchers better understand vast amounts of virus-related data and connect findings with other similar results.

In August, Melax also received another $300,000 grant from the National Institute of Allergy and Infectious Diseases to develop NLP-based algorithms that will "model, extract and synthesize vaccine misinformation from multiple popular social media sources," according to a statement. Melax will also develop a visualization that presents its findings on the misinformation into a compressible format.

"This is a very real topic affecting culture at present," Andre Pontin, CEO at Melax Tech, says in a statement. "And shows that we as a collective business and group of experts continue to be on the cutting-edge of science in the NLP and AI domain."

Trending News